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Accepted 10 January 2011AbstractTraditional Chinese medicines have been widely investigated for the treatment of Alzheimer’s disease (AD) because none of the current
therapiesdeither the cholinesterase inhibitors or antagonist of N-methyl-D-aspartate receptorsdhas profound effects on halting the progression
of AD. In recent years, scientists have isolated many active compounds from herbs, which can alleviate dementia and neurodegenerative
syndrome with fewer side effects than conventional drugs and, thus, are regarded as promising drug candidates for AD therapy. In this review, we
summarize the latest research progress on six herbs for AD therapydHuperzia serrata, Amaryllidaceae family, Ginkgo biloba, Uncaria
rhynchophylla, Polygala tenuifolia, and Salvia officinalisdand focus on the analysis of their active components and possible mechanisms of
pharmacological actions on AD.
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With the rapid increase in the aged population in recent
years, senile dementia has become one of the world’s impor-
tant public health issues. Alzheimer’s disease (AD) is the most
common type of senile dementia, a neurodegenerative disease
characterized by progressive memory loss and cognitive
impairment in the elderly [1]. Pathological characterization of
AD includes extracellular deposition of senile plaques;
formation of intracellular neurofibrillary tangles; and lesions
of cholinergic neurons together with synaptic alterations in
cerebral cortex, hippocampus, and other brain regions [2]. At* Corresponding author. School of Chinese Medicine, College of Chinese
Medicine, China Medical University, Taichung 40402, Taiwan.
E-mail address: jinn@mail.cmu.edu.tw (T.-R. Jinn).
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progress of AD are apoptosis, oxidative stress, mitochondrial
dysfunction, inflammatory responses, and disturbance of
energy metabolism homeostasis. However, the severe loss of
function of the cholinergic neurons correlating with dementia
in AD is still not clearly understood [3]. Current clinical drugs
administered to slow down the progress of the deterioration in
AD patients include cholinesterase inhibitors and agonists of
N-methyl-D-aspartate receptors (NMDA) [4], but none of these
therapies has profound effects on halting the advancement of
AD. As a consequence, it is very important to identify novel
and pharmacotherapeutic drugs for AD.
Traditional Chinese medicine (TCM) is practiced in the
Chinese health care system for more than 2,000 years. Many
active pharmacological compounds from Chinese herbal
medicines have been identified for the treatment of various
diseases, including diabetes, microbial infections, allergy,cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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have been claimed to enhance human health by stimulating
blood circulation and by supplementing vital energy. Thus,
Chinese herbs provide a good source of drugs for screening
that may be beneficial for AD patients. In recent years,
scientists have isolated many novel compounds from herbs,
some of which improve dementia with fewer side effects than
conventional drugs and are regarded as promising anti-AD
drugs. In this review, we summarize the latest research prog-
ress on Chinese herbal medicines showing their possible
pharmacological actions in alleviating dementia and AD.
Huperzia serrata (Qian Ceng Ta)
Huperzia serrata has been traditionally used to relieve pain
and as an antidote for poisoning as well as for the treatment of
contusions, strains, swelling, and schizophrenia. It has been
found that active compoundsdthe Lycopodium alkaloidsd
from H serrata include huperzine A (Hup A, Fig. 1); huper-
zine B (Hup B); N-methyl-Hup B; huperzinine; carinatumin
A; and carinatumine B [5], and among these, Hup A is
considered the most potent acetylcholinesterase (AchE)
inhibitor. Hup A had been approved by the Food and Drug
Administration to treat AD in the 1990s. Compared with other
approved drugs, such as tacrine, donepezil, galanthamine, and
rivastigmine, Hup A not only exhibits the most powerful
activity as an anti-AchE agent, it also acts better in penetrating
the bloodebrain barrier. Besides, it also shows higher oral
bioavailability and has longer duration of anti-AchE activity
[6]. More interestingly, Hup A is also found to be an effective
cognition enhancer. It has been demonstrated that Hup A
exerts multiple neuroprotective effects, in which the mecha-
nisms may involve the activation of both muscarinic and
nicotinic acetylcholine receptors; enhancement of the
production of neurotrophic factors; as well as blocking of
overstimulated NMDA receptors. It has also been known to
regulate the activity of antioxidative enzymes, to attenuate
mitochondrial dysfunction, and to scavenge reactive oxygen
species [7]. Therefore, Hup A is effective in improving
cognitive impairments in multi-infarct dementia, brain trauma,
schizophrenia, and benign senescent forgetfulness [6]. These
neuroprotective effects may be the result of the upregulation of
c-jun gene and downregulation of bcl-2 gene [8,9]; the upre-
gulation of nerve growth factor secretion and its downstream
signaling; the inhibition of oxidative stress; and theCH
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Fig. 1. The chemical structure of huperzine A isolate from the club moss
Huperzia Serrata, known as Qian Ceng Ta. The club moss is usually found in
deep-shaded forests. Traditional Chinese medicine has used this plant in tea
for centuries to heal a variety of illnesses, including seizures, brain swelling,
fevers, and inflammation.improvement in energy metabolism [10]. More importantly,
Hup A can modulate the processing of amyloid precursor
protein (APP) by the regulation of protein kinase C [11] and
the promotion of the nonamyloidogenic pathway of APP
metabolism and reduction in the production of Ab amyloid.
Clinical studies have demonstrated that Hup A can signifi-
cantly improve the memory of elderly people and AD patients
without any notable side effects [12]. In summary, all the
advantageous effects of Hup A may be attributed to its potent,
reversible, and selective inhibition of AchE [13,14]. Its
potency in AchE inhibition is adequate to treat AD and other
relevant cognitive impairments.
Amaryllidaceae family
Plants belonging to the Amaryllidaceae family have been
traditionally used in China for the treatment of poisonous
snakebites, acute laryngeal infection, rheumatoid arthritis,
paralysis, and muscle diseases brought about by infantile
paralytic sequela [15]. One of the well-studied alkaloids from
Amaryllidaceae is galanthamine (Fig. 2), which is a tertiary
alkaloid originally extracted from the bulbs of Galanthus
woronowii. Galanthamine was also isolated from other herbs
of the Amaryllidaceae family, such as Lycoris radiate, Lycoris
aruea, and Lycoris squamigeric [16]. It acts as a selective,
reversible, and competitive inhibitor of AchE. Previous studies
have indicated that galanthamine may potentiate memory
deficits [16,17]. Furthermore, the compound has the ability to
selectively stimulate or/and modulate neuronal nicotinic
acetylcholine receptor, which could facilitate an increase in
the synthesis of neurotrophic factors and protect neuronal cells
against hazardous effects of oxidative stress and injury
[18,19]. Moreover, the combination of galanthamine and
nicotine works synergistically in inhibiting microglia activa-
tion [20]. A clinical trial has confirmed the efficacy and safety
of galanthamine in the treatment of AD [21]. Thus, the use of
galanthamine for the treatment of mild to moderate AD has
been approved by the State Food and Drug Administration in
China and the Food and Drug Administration in the United
States. Generally, galanthamine is a natural product with
multiple molecular targets as it acts in the regulation of
cholinergic transmission and in easing oxidative stress [22];12a
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Fig. 2. The chemical structure of galanthamine extract from the bulbs of
Galanthus woronowii, plants of the Amaryllidaceae family, which have been
customarily used in Traditional Chinese medicine for the treatment of
poisonous snakebites, acute laryngeal infection, rheumatoid arthritis, paralysis,
and muscle diseases brought on by infantile paralytic sequela.
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antiapoptotic protein expression [26e28].
Ginkgo biloba
Ginkgo biloba L. has customarily been used in China as
a medicine to promote vitality in humans. It is well known that
many active components exist in G biloba L.; a few of them
are ginkgolides, bilobalide, ginkgolic acids, and ginkgo
flavone glycoside (Fig. 3) [29]. It is noteworthy to cite that the
leaf extract of G biloba (EGb), labeled EGb761, possesses the
capacity to treat a variety of neurological disorders, including
AD and age-related dementia [30]. EGb761 is a mixture of
flavonoids, terpenes, and organic acids. It was reported that the
antioxidant activity of EGb761 may play a substantial role in
neuroprotection by decreasing bax/bcl-2 ratios [31], reversal
of ischemia-induced reductions of cycloxygenase III mRNA in
hippocampal CA1 neurons, inhibition of nitric oxide synthesis,
scavenging of free radicals, and attenuation of lipid perox-
idation [32,33]. Consistent with the aforementioned findings,
many experimental evidences have demonstrated that EGb761
has many pharmacological effects, including amelioration of
mitochondrial dysfunction, blockade of the NMDA receptor,
scavenging of free radicals, lowering of oxidative stress,
reduction of neural damages, reduction of platelet aggregation,
anti-inflammation, and anti-aging [34e36].
Uncaria rhynchophylla
Uncaria rhynchophylla Havil is a medicinal plant that has
been used to alleviate neuropsychiatric symptoms, such as
headache, dizziness, vertigo, and tinnitus. The extracts of this
herb contains several different compounds, such as corynox-
eine, rhynchophylline, isorhynchophylline, isocorynoxeine,
geissoschizine methyl ether, hirsuteine, and hirsutine. Some of
these mentioned alkaloids have been regarded as neuro-
protective compounds [37]. Because one of the etiologies of
AD is progressive deposition of insoluble highly neurotoxic
Ab proteins in the form of senile plaques in the central
nervous system [38], attractive therapeutic strategies for the
treatment of AD would be the following: inhibition of AbR
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Fig. 3. The chemical structure of ginkgo flavone glycoside, including
kaempferol, quercetin (rutin), and isorhamnetin, extracts from Ginkgo biloba
L. Ginkgo biloba L. has long been used in China as a traditional medicine to
promote the vital energy of humans. R¼O: kaempferol-3-O-rutinoside;
R¼OH: quercetin-3-O-O-rutinoside (rutin); R¼OCH3: isorhamnetin-3-O-
rutinoside.generation, prevention of Ab fibril formation, or destabiliza-
tion of preformed Ab fibrils. It was reported that the extracts
from U rhynchophylla have significant inhibitory and desta-
bilizing effects on Ab fibril than other Chinese medical herbs
[39]. Hence, U rhynchophylla could have the potential to be
a novel therapeutic agent for AD prevention in the future.
Polygala tenuifolia
Herbal medicines have long been used for improving
cognitive functions and for the treatment of memory loss. Of
these, P tenuifolia Willdenow is one of the most frequently
used medicinal herbs for memory loss in TCM. In addition,
P tenuifolia has been known to have therapeutic effects, such
as expectorant, sedative, antipsychotic, and anti-inflammatory
[40]. The polygalasaponins (oleanane-type saponins) in the
dried root of P tenuifolia plant can inhibit cyclic adenosine
monophosphate production [41]. In addition to this, it was
accounted that an effective compound from the dried root of
P tenuifolia, tenuifolin, could inhibit AchE activity or could
enhance cholinergic neurotransmission [42]. It had also been
reported that tenuifolin could penetrate the bloodebrain
barrier and improve cognitive impairment through elevation of
the cholinergic system by blocking acetylcholine hydrolysis
[42]. Moreover, a decrease in the secretion of Ab1e40 and
Ab1e42 by tenuifolin was also reported [43]. These important
findings will facilitate the development of tenuifolin or its
derivatives as pharmaceuticals in the treatment and manage-
ment of AD.
Salvia officinalis
Salvia officinalis L. is a multifunctional Chinese medicine
herb. It has a longstanding application as an antibiotic, anti-
hydrotic, astringent, and antifungal agent. The plant, S offici-
nalis, is well known for its antioxidative properties [44] for the
reason that its leaf extract has its main constituent, ursolic acid
(Fig. 4), a pentacyclic triterpenoid carboxylic acid, which can
effectively reduce the level of lipid peroxidation and effi-
ciently reverse D-galactose-induced learning and memory
impairment [45]. Because oxidative stress is linked with
damage and progressive cell death occurring in neurodegen-
erative disorders, such as Parkinson’s disease and AD [46],
a recent clinical trial had demonstrated that the extracts of
S officinalis are effective in treating mild to moderate AD [47].
Moreover, ursolic acid also efficaciously inhibits AchE
activity in vitro [48]. These results implied that the extractsFig. 4. The chemical structure of ursolic acid, a pentacyclic triterpenoid
carboxylic acid, which can effectively reduce the level of lipid peroxidation
and efficiently reverse D-galactose-induced learning and memory impairment.
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protection of neurons by reducing oxidative stress and boost-
ing memory through inhibitions of AchE activity. Likewise,
rosmarinic acid, a phenolic derivative of caffeic acid, is also
found in water extracts of S officinalis, which exhibits a dose-
dependent stalling of the Ab fibril formation from Ab1e40 and
Ab1e42 as well as Ab fibril aggregation, and it can also
destabilize the integrity of Ab fibrils [49,50]. Thus, the
S officinalis L. extract could be a promising drug candidate for
dementia and AD therapy.
Conclusion
The treatment of AD remains a challenge in the modern
day medicine because of the incomplete understanding of its
pathogenesis, and still, none of the current therapeutic
modalities can successfully halt the progression of AD at an
early stage. Thus, perpetual extensive studies to search for new
active extracts or components derived from various plants for
the treatment of AD are carried out. Indeed, some active
extracts or components from herbs are highly potent and
multitargeted with low toxicity for the treatment of AD,
although the underlying molecular mechanisms have not been
fully elucidated. These herbs are regarded as new and prom-
ising sources of potential anti-AD drugs. Generally, these
encouraging preclinical and clinical trials suggest that TCM is
a promising candidate for the treatment of neurodegenerative
diseases, such as dementia and AD. This “conventional” TCM
also provides a new direction in drug development to obtain
advanced therapeutic agents that possess both high efficacy
and safety for the treatment of AD other than the conventional
“western” medicine. Interestingly, recent studies have impli-
cated memantine, an analog of amantadine, which can inhibit
the internal ribosome entry site (IRES) of piconavirus-medi-
ated translation [51] and can also prevent the expression of
APP and tau through the inhibition of a translation initiation
mechanism that is mediated by the IRES [52,53]. The IRES of
tau and APP could be new targets to screen the TCM that can
act as potential therapeutic drugs for AD.
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